{"page":{"totalFilteredElements":84},"studies":[{"active":true,"description":"<div>Register und Biomaterialdatenbank f&#252;r reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe H&#228;matologie und Onkologie (OSHO)</div><div><br /></div><div>DRKS00030561</div>","eudractNumber":null,"id":8286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-14T13:56:45+02:00","shortTitle":"T-NHL Register (OSHO & GLA)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-502681-24-00","id":7759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05338775","phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2022-07-06T15:14:55+02:00","shortTitle":"TRIMM-3, 64407564MMY1005","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilt-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in combination with Daratumumab SC (Tec-D) Following Induction with Daratumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnose Multiple Myeloma","eudractNumber":"2023-505792-71","id":9857,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-05-08T09:13:35+02:00","shortTitle":"aMMbition","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"&#160;A Phase 3, Randomized, Open Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with relapesd, refractory Multiple Myeloma (KT-US-679-0788,&#160;iMMagine-3)","eudractNumber":"2024-511188-26","id":9859,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06413498","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-06-13T10:01:57+02:00","shortTitle":"iMMagine-3","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}